Find A Clinical Trial
Disease Type: Breast
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)
Principal Investigator
Anne Favret, MDpostMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)
Principal Investigator
Anne Favret, MD(V3002401) ARTEST – A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with Androgen Receptor Nuclei Staining greater than or equal to 40% Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK…
Principal Investigator
Anne Favret, MDPHASE 1b/2 DOSE-CONFIRMING, MULTIPART, MULTICENTER STUDY OF CFI-402257 AS A SINGLE AGENT IN ADVANCED SOLID TUMORS AND IN COMBINATION WITH FULVESTRANT IN PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER AFTER DISEASE PROGRESSION ON PRIOR CDK4/6 AND ENDOCRINE THERAPY
Principal Investigator
Alexander I. Spira, MD, PhD, FACPIsabelle Le, MD, is board certified in Medical Oncology and Hematology. She is a member of the American Society of Clinical Oncology (ASCO). As a medical oncologist, Dr. Le has a strong focus in the treatment and management of breast cancer. As a breast specialist, Dr. Le works with a multidisciplinary team, which includes breast…
A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients with Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies
Principal Investigator
Shruti Tiwari, MDSERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Principal Investigator
Anne Favret, MDA PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Principal Investigator
Anne Favret, MDRandomized, Non-Comparative Phase 1/2 Study of NUV-422 in Combination with Fulvestrant in Patients with Hormone Receptor-Positive Epidermal Growth Factor Receptor2-Negative (HR+ HER2-) Advanced Breast Cancer